Clinical trials: LOCALLY ADVANCED RECTAL CANCER
CRC (Colorectal Cancer)
Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
The goal of this clinical trial is to learn if SHR-1701 combine with chemoradiotherapy works to treat severe CRC. Participants will take: Induction: SHR-1701 combined with CAPOX for one cycle.
- Trial name
- MA-CRC-II-018 (NCT07478731)
- Testing
- SHR-1701 neoadjuvant
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hong Qiu
Locally Advanced Rectal Carcinoma
Preoperative, Adaptive Radiotherapy Concomitant to Chemotherapy for Rectal Adenocarcinoma (Adaptive Rectal Cancer Trial 02)
The aim of this clinical study is to increase the rate of pathological responses up to 70% by means of improved patient selection operated by a radiobiological index called ERI_TCP and by an increase in the dose of radiotherapy…
- Trial name
- NCT07580027
- Testing
- Preoperative, adaptive radiotherapy
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- IRCCS San Raffaele
Locally Advanced Rectal Cancer
Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
The study evaluates the addition of Amifostine to capecitabine and irinotecan in neoadjuvant chemoradiation(CRT) in locally advanced rectal cancer.
- Trial name
- NCT03702985
- Testing
- Radiation, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
- Conditions
- ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
- Trial name
- NCT07540572
- Testing
- IDE574, Fulvestrant injection
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- IDEAYA Biosciences
Cancer, Tumor, Solid
Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of subcutaneously administered JK08 in patients with unresectable locally, advanced…
- Conditions
- Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer
- Trial name
- NCT05620134
- Testing
- JK08, Pembrolizumab, Lenvatinib Pill
- Where
- 11 sites in Belgium, Spain
- Volunteers
- 263 people
- Sponsor
- Salubris Biotherapeutics Inc
Rectal Cancer, Radiation Oncology
Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer
The question of how to administer adequate chemotherapy and immunotherapy to synchronise hypofraction radiotherapy （HFRT） treatment strategy to maximise the benefits of neoadjuvant therapy for the improved prognosis of patients…
- Trial name
- NCT05176964
- Testing
- split-course HFRT, CAPOX chemotherapy, Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University Union Hospital
Locally Advanced Colorectal Cancer, Metastatic Colorectal Cancer
CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer
This prospective, single-arm study aims to investigate the efficacy and safety of CapeOX combined with anti-PD1 antibody plus dihydroartemisinin as neoadjuvant or conversion therapy for pMMR/MSS locally advanced and metastatic…
- Trial name
- NCT07801352
- Testing
- Capecitabine, Oxaliplatin, Dihydroartemisinin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Changzheng Hospital
Rectal Cancer Patients
Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study
This study aims to evaluate the efficacy and safety of neoadjuvant short-course radiotherapy combined with Retlirafusp alfa and CAPOX chemotherapy in the treatment of locally advanced rectal cancer.
- Trial name
- NCT07663071
- Testing
- Short-course radiotherapy combined with Retlirafusp alfa and CAPOX chemotherapy
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Harbin Medical University
Locally Advanced Rectal Cancer (LARC)
Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial
The goal of this clinical trial is to learn whether adding ipilimumab N01 to standard pre-surgery treatment with radiation, chemotherapy, and sintilimab can improve outcomes for people with low- or intermediate-risk, locally…
- Trial name
- NCT07879599
- Testing
- Ipilimumab & Sintilimab, Sintilimab
- Volunteers
- 120 people
- Sponsor
- Yao Hongwei
Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life.
- Conditions
- Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8
- Trial name
- NCT06265285
- Testing
- Home Health Encounter, Nivolumab, Patient Monitoring
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Locally Advanced Rectal Cancer (LARC)
Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer
Standard treatment for patients with proficient mismatch repair (pMMR) / microsatellite stable (MSS) locally advanced rectal cancer (LARC) consists primarily of neoadjuvant chemoradiotherapy followed by radical surgery.
- Trial name
- NCT07581626
- Testing
- SCRT+targeted therapy+immunotherapy+chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer
Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer
This phase I trial studies the side effects and best dose of fluorouracil when given together with radiation therapy followed by combination chemotherapy before and after surgery in treating patients with rectal cancer that has…
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Rectal Adenocarcinoma
- Trial name
- NCT02270606
- Testing
- intensity-modulated radiation therapy, fluorouracil, oxaliplatin
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Virginia Commonwealth University
Locally Advanced Rectal Cancer (LARC)
Development and Validation of a Post-operative Risk Of Local Recurrence Model Integrating Serology and Evalution (PROMISE) in Local Advanced Rectal Cancer Receiving Neoadjuvant Therapy: a Multicenter Study
Local recurrence (LR) in locally advanced rectal cancer (LARC) correlated with poor survival and impaired quality of life. The aim of this study was to develop and validate machine learning (ML) models integrating…
- Trial name
- PROMISE model (NCT07351708)
- Volunteers
- 2,315 people
- Sponsor
- Cai Zerong
Colorectal Cancer
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of combining cemiplimab, cemiplimab/fianlimab, or cemiplimab/REGN7075 with capecitabine/oxaliplatin (CAPOX) for the neoadjuvant treatment of patients with…
- Trial name
- NCT07281768
- Testing
- Oxaliplatin, Capecitabine, Cemiplimab
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Carcinoma
PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer
In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with PD-1 antibody following preoperative Chemoradiotherapy with capecitabine for pMMR/MSS rectal cancer staged as locally advanced…
- Trial name
- NCT04833387
- Testing
- PD-1 antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer, Cervical Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived engeneered T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma
- Trial name
- NCT05973487
- Testing
- TSC-204-A0201, TSC-204-C0702, TSC-200-A0201
- Where
- 21 sites in United States
- Volunteers
- 840 people
- Sponsor
- TScan Therapeutics, Inc.
Rectal Cancer
Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
This prospective, single-center, randomized controlled trial evaluates whether online adaptive radiotherapy (ART) with a sequential boost to both the primary rectal tumor and clinically involved lymph nodes improves pathologic…
- Trial name
- NCT06246344
- Testing
- Online Adaptive Radiotherapy With Sequential Boost, Conventional Non-Adaptive IMRT, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shandong Cancer Hospital and Institute
Colorectal Cancer, Colorectal Carcinoma
Nelfinavir, a Phase I/Phase II Rectal Cancer Study
The aim is to study safety and activity of nelfinavir , added to standard chemoradiotherapy in patients with locally advanced rectal cancer.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- Nelfinavir (NCT00704600)
- Testing
- nelfinavir
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Maastricht Radiation Oncology
CRC (Colorectal Cancer), Melanoma (Skin Cancer)
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary antitumor activity of TGI-5 as monotherapy and in combination with Nivolumab in subjects with…
- Conditions
- CRC (Colorectal Cancer), Melanoma (Skin Cancer), HCC - Hepatocellular Carcinoma, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- TGI5 (NCT07376707)
- Testing
- TGI-5
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.
Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer
QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer
This is a multicenter, prospective, phase II study evaluating total neoadjuvant therapy (TNT) consisting of short-course radiotherapy (SCRT; 5×5 Gy) followed by QL1706 (a bifunctional MabPair antibody targeting PD-1 and CTLA-4…
- Conditions
- Locally Advanced Rectal Cancer (LARC), Mismatch Repair-Proficient (pMMR) Rectal Cancer, Non-metastatic Rectal Cancer
- Trial name
- NCT07175636
- Testing
- Drug: QL1706 Drug: mFOLFOX6 Radiation: Short-Course Radiotherapy (SCRT)
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University